MOUNTAINSIDE, N.J., July 17 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (OTC: NHGI) today announced that its wholly owned subsidiary Proteoderm, Inc. is exhibiting at the 16th Annual International World Congress on Anti-Aging Medicine being held in Washington, DC on July 17 -- 19, 2008. Dr. Kenneth Steiner, MD, MBA was invited to speak as a scientific keynote panelist. Dr. Steiner will introduce the company's first commercial line of cosmoceuticals, which will be sold through medical sales representatives for use by dermatologists, plastic surgeons and other licensed health care professionals.
Proteoderm licenses patented technologies involving stem cells and their derivatives developed by National Stem Cell Holding, Inc. Proteoderm produces, designs and synthesizes proteins, polypeptides and growth hormones secreted by stem cells trademarked under Secreted Matrix(TM) and Matrix NC 138(TM) and incorporates them into uniquely formulated personal care products.
Proteoderm has created an anti-aging and anti-wrinkle product line that enhances the skin's firmness and elasticity and promotes the skin's natural moisture production activity. Unlike the array of products on the market today that reduce the appearance of wrinkles by artificial moisturizing and plumping, Proteoderm's products are the first to provide Matrix NC 138(TM) to the skin surface. Proteoderm's cosmoceutical kits will contain day and night creams and an under-eye serum containing the patented Matrix NC 138(TM) as well as an exfoliant and a cleanser.
Dr. Steiner stated, "During pregnancy, the human body increases the production specific proteins in response to secretions produced by stem cells. These specific proteins are known to effect specific receptors in the skin that enhance the production of facial collagen. Proteoderm has developed compositions including topical formulations containing these naturally occurring proteins which assist in counteracting the adverse consequences of aging."
"We are very excited to commercialize Proteoderm's first line of cosmoceuticals. We look forward to enhancing shareholders' value as we introduce our unique product. This is a turning point in the maturation of our company," said CEO of National Stem Cell Holding, Inc. Michael Cohen.
TO LEARN MORE ABOUT OUR PRODUCTS VISIT HTTP://WWW.PROTEODERM.COM.
About National Stem Cell Holding, Inc.
National Stem Cell Holding, Inc. is a biotechnology company focused on the development and commercialization of cell therapeutics primarily for diabetes and cardiac disease, and cosmetics derived from stem cells. For more information, visit http://www.proteoderm.com, and http://www.proteonomix.com.
"Safe Harbor Statement"
Under The Private Securities Litigation Reform Act of 1995: The
statements in the press release that relate to the company's expectations
with regard to the future impact on the company's results from new products
and products in development are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. The
results anticipated by any or all of these forward-looking statements may
not occur. The Company undertakes no obligation to publicly release the
result of any revisions to these forward-looking statements that may be
made to reflect events or circumstances after the date hereof, or to
reflect the occurrence of unanticipated events or changes in the Company's
plans or expectations.
Phone: (973) 544-6116
|SOURCE National Stem Cell Holding, Inc.|
Copyright©2008 PR Newswire.
All rights reserved